Cat. No. 0414
Alternative Name: Tyrphostin AG 490
Chemical Name: (E)-2-Cyano-3-(3,4-dihydrophenyl)-N
Biological ActivitySelective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Inhibitor of JAK2, JAK3/STAT, JAK3/AP-1 and JAK3/MAPK pathways and potently inhibits cytokine-independent cell growth in vitro and tumor cell invasion in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Gazit et al (1991) Tyrphostins. 2. Heterocyclic and α-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID: 1676428.
Meydan et al (1996) Inhbition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature 379 645. PMID: 8628398.
Wang et al (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J.Immunol. 162 3897. PMID: 10201908.
Abe et al (2009) The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int.Immunopharmacol. 9 870. PMID: 19327411.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: AG 490, supplier, JAK2, JAK3, inhibitors, EGFR-kinase, JAK, Kinase, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, Janus, Activated, Kinases, Epidermal, Growth, Factors, Receptors, ErbB, Her, EGFR, RTK, Receptor, Tyrosine, RTKs, AG490, Tyrphostin, AG, 490
Find multiple products by catalog number
New Products in this Area
EphA4 receptor tyrosine kinase antagonist; neuroprotectivePD 90780
Inhibits NGF binding to p75NTRLM11A 31 dihydrochloride
Nonpeptide p75NTR ligand; neuroprotectiveToceranib
Potent PDGFR and VEGFR inhibitorNVP ADW 742
ATP-competitive inhibitor of IGF1RKRCA 0008
Potent Ack1 and ALK dual inhibitor; orally bioavailableDDR1-IN-1 dihydrochloride
Selective DDR1 inhibitor
November 15 - 19, 2014
Washington D.C., USA